Search | Page 13 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions.

    ... The treatment of myelodysplastic syndromes (MDS) involves a complex algorithm that depends on multiple ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    ... on long-term outcomes of patients with lower risk myelodysplastic syndromes (MDS) and chromosome 5q deletion (del(5q)) is unclear. This ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine.

    ... BACKGROUND: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Emerging immunosuppressive drugs in myelodysplastic syndromes

    ... Myelodysplastic syndromes (MDS) are characterized by dysplastic morphologic features and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Established and novel agents for myelodysplastic syndromes

    ... The myelodysplastic syndromes (MDS) are the most commonly diagnosed myeloid malignancy, with ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Myelodysplastic syndromes, version 2.2015

    ... The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

    ... and decitabine are standard therapy for myelodysplastic syndromes (MDS), and are often used to treat patients with acute myeloid ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. How we treat higher-risk myelodysplastic syndromes

    ... Higher-risk myelodysplastic syndromes (MDS) are defined as patients who fall into higher risk group ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.

    ... mechanisms contribute essentially to the pathogenesis of myelodysplastic syndromes (MDS) and may trigger disease-progression to secondary acute ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

    ... decitabine have changed the treatment landscape of myelodysplastic syndromes (MDS) since their approval by the United States Food and Drug ...

    Research Article last updated 07/20/2018 - 5:14pm.